Back to Search
Start Over
Risk–Benefit Analysis of Primary Prophylaxis Against Pneumocystis Jirovecii Pneumonia in Patients With Rheumatic Diseases Receiving Rituximab.
- Source :
- Arthritis & Rheumatology; Nov2023, Vol. 75 Issue 11, p2036-2044, 9p
- Publication Year :
- 2023
-
Abstract
- Objective: To identify a specific population of patients with rheumatic diseases receiving rituximab treatment for whom the benefit from primary prophylaxis against Pneumocystis jirovecii pneumonia (PJP) outweighs the risk of adverse events (AEs). Methods: This study included 818 patients treated with rituximab for rheumatic diseases, among whom 419 received prophylactic trimethoprim/sulfamethoxazole (TMP/SMX) with rituximab, while the remainder did not. Differences in 1‐year PJP incidence between the groups were estimated using Cox proportional hazards regression. Risk–benefit assessment was performed in subgroups stratified according to risk factors based on the number needed to treat (NNT) to prevent 1 case of PJP and the number needed to harm (NNH) due to severe AEs. Inverse probability of treatment weighting was applied to minimize the confounding by indication. Results: During the 663.1 person‐years, there were 11 PJP cases, with a mortality rate of 63.6%. Concomitant use of high‐dose glucocorticoids (≥30 mg/day of prednisone or equivalent during 4 weeks after rituximab administration) was the most important risk factor. The PJP incidence (per 100 person‐years) was 7.93 (95% confidence interval [95% CI] 2.91–17.25) in the subgroup receiving high‐dose glucocorticoids compared with 0.40 (95% CI 0.01–2.25) in the subgroup without high‐dose glucocorticoid use. Although prophylactic TMP/SMX significantly reduced the overall PJP incidence (HR 0.11 [95% CI 0.03–0.43]), the NNT to prevent 1 case of PJP (146) was higher than the NNH (86). In contrast, the NNT fell to 20 (95% CI 10.7–65.7) in patients receiving concomitant high‐dose glucocorticoids. Conclusion: The benefit associated with primary PJP prophylaxis outweighs the risk of severe AEs in patients with rheumatic diseases receiving rituximab and concomitant high‐dose glucocorticoid treatment. [ABSTRACT FROM AUTHOR]
- Subjects :
- DRUG therapy for rheumatism
RITUXIMAB
GLUCOCORTICOIDS
RESEARCH
CO-trimoxazole
CONFIDENCE intervals
PNEUMOCYSTIS pneumonia
DISEASE incidence
RETROSPECTIVE studies
ACQUISITION of data
RISK assessment
DESCRIPTIVE statistics
MEDICAL records
PREDNISONE
DATA analysis software
PROPORTIONAL hazards models
LONGITUDINAL method
Subjects
Details
- Language :
- English
- ISSN :
- 23265191
- Volume :
- 75
- Issue :
- 11
- Database :
- Complementary Index
- Journal :
- Arthritis & Rheumatology
- Publication Type :
- Academic Journal
- Accession number :
- 173312710
- Full Text :
- https://doi.org/10.1002/art.42541